Kornimate/medical-research-clean huggingface dataset:
client and provider preferences for hiv care

Conditions: HIV Infections

Summary: this study will investigate preferences for hiv care among participants enrolled in the "study to evaluate the feasibility of community-based test and treat strategies among men who have sex with men and transgender women to increase the uptake of hiv testing and treatment services in thailand" through a model involving linked strategies: the study takes place in four provinces at six sites affiliated with the thai red cross aids research center (trcarc): bangkok (rsat and swing), chiang mai (caremat), chonburi (swing and sisters) and songkhla (rsat). these are all community-based drop-in centers, targeting msm and tgw. participants who are enrolled in the study at any of the trcarc affiliated sites and who were tested hiv-positive will be invited to participate in the current questionnaire study.

this will be a cross-sectional questionnaire study. a self-administered questionnaire will be used to assess their satisfaction with current clinical services, preferences for location, frequency and provider of hiv services, as well as expectations and concerns. furthermore, staff working at the different hiv-care to community-based organizations (cbos) and the health care workers providing hiv services will be invited to participate as well. they will also be asked to complete a self-administered questionnaire to assess knowledge and attitude, preferences for location, frequency and provider of hiv services, as well as expectation and concerns. all data collected, from patients, as well as from staff, will be anonymous.

Eligibility criteria:
inclusion criteria: * enrolled in the community led test and treat study at either rsat or swing * according to the inclusion criteria of the community led test and treat study, participants will be at least 18 years of age * hiv-infected and receiving art * willing to participate in the survey exclusion criteria: n/a
sorafenib plus s-1 in advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: primary objective: 1. to define the recommended dose for phase ii study of s-1 combined with sorafenib 2. to evaluate the dose-limiting toxicities of the combination therapy secondary objectives: 1. to characterize the pharmacokinetics (pk) of sorafenib and s-1 in the combination therapy 2. to investigate the impact of genetic polymorphisms of metabolic genes on the pk of sorafenib and s-1, respectively, as well as on the toxicity profile of the combination. 3. to determine the changes of biomarkers between pre- and post-treatments.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven metastatic or locally advanced malignant solid tumors, which are refractory to current standard systemic treatment. * have measurable lesion. * 20-75 y/o. * ecog performance score no more than 2. * life expectancy \> 12 weeks. * adequate hematopoietic, hepatic and renal functions. 1. hemoglobin \> 9.0 g/dl 2. absolute neutrophil count \> 1,500/mm3 3. platelet count 100,000/ mm3 4. total bilirubin \< 1.5 times the upper limit of normal (uln) 5. alt and ast \< 2.5 x uln 6. serum creatinine \< 1.0 x uln * recovery from prior therapy that given \> 4 weeks before enrolment. * no pregnancy and breast-feeding. * signed informed consent. exclusion criteria: * severe cardiovascular disorders. * pulmonary fibrosis or interstitial pneumonia. * hiv infection. * active infection. * major anti-cancer treatment within 4 weeks of study entry. * exposure to the current investigational agent before. * known or suspected allergy to the current investigational agent. * unable to swallow oral medications. * substance abuse, medical, psychological or social conditions interfering with the patient's participation or evaluation of the study results. * any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study. * symptoms of bowel obstruction, malnutrition, splenomegaly. * receiving active anti-coagulant therapy. * patients with concurrent cyp 2a6 and/or cyp 3a4 or 3a5 inducers or inhibitors; a minimal of 2 weeks wash-out period required.

Keywords: sorafenib s1 advanced solid tumors rd mtd dlt pk pg biomarker
evaluation of a pathway on the evolution of renal function in patients with advanced chronic kidney disease

Conditions: Kidney Function Issue

Summary: the number of incident and prevalent patients with end stage renal disease on dialysis treatment is increasing in france and worldwide. a quarter of dialysis patients are initiating dialysis urgently through central venous catheters and the number of patients registered in the waiting list for renal transplantation before dialysis initiation is very low. this is also reflected in the very low number of pre-emptive renal transplantations. in order to reduce the number of dialysis patients, the french state has induced a national program proposing a multidisciplinary care pathway including the nephrology visits and at least one consultation with a dietitian and a specialist renal nurse in all patients with chronic kidney disease stage 4 and 5. the aim of this single-center retrospective study is to evaluate the influence of the complete, partial or no participation in this program on the evolution of renal function and clinicobiological parameters in this group of patients.


Eligibility criteria:
inclusion criteria: * all stage 4 and 5 chronic kidney disease patients that were included in the program from 01/01/2021 to 31/12/2021 in the clinics of aura sante exclusion criteria: * patients without a medical follow up during this year (2021) * patients with insufficient or no data during the 24 month of follow up period * active treatment with corticosteroids, cytotoxic or immunosuppressive drugs, ongoing infection, autoimmune disease or active tumor process
a study to evaluate the effects of pharmacological chaperones in cells from patients with pompe disease

Conditions: Pompe Disease; Glycogen Storage Disease Type II

Summary: the purpose of this study is to see how molecules called pharmacological chaperones affect the cells of patients with pompe disease. the study will last 1 or 2 visits which will include a blood collection, urine collection, and two skin biopsies. information will also be collected from the medical records about disease history and diagnosis. patients will not receive any study medication.

the study is designed to evaluate the response of cell lines derived from blood and skin tissue from pompe patients to pharmacological chaperones. samples of blood and skin tissue will be obtained to make cell lines that will be used to test pharmacological chaperones. the study will include patients with early and late-onset pompe disease.

Eligibility criteria:
inclusion criteria: * male or female of any age * confirmed diagnosis of pompe disease (early or late-onset) * clinically stable * written informed consent by subject or legal representative exclusion criteria: * other significant disease or otherwise unsuitable for the study, as determined by the investigator
study of roxadustat conversion in participants receiving stable erythropoiesis-stimulating agent (esa) or as initial anemia treatment in chronic dialysis participants

Conditions: Anemia Associated With End Stage Renal Disease (ESRD)

Summary: the purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among chronic dialysis participants converted from esa therapy or who are esa-naïve.


Eligibility criteria:
key inclusion criteria: * receiving chronic dialysis for end stage renal disease (esrd) * vascular access must be a functioning native arteriovenous fistula or graft with adequate flow in the opinion of the investigator, or permanent tunneled catheter * screening hemoglobin criteria (based on central lab value; measured within 10 days prior to initiating roxadustat treatment: participants converting from cera: screening heamoglobin was between 9.0 to 12.0 g/dl; participants initiating anemia treatment: \<10.0 g/dl * ferritin ≥ 50 nanograms (ng)/milliliter (ml), transferrin saturation (tsat) ≥ 10% at screening * participant's alanine aminotransferase (alt) and aspartate aminotransferase (ast) are ≤3 x upper limit of normal (uln), and total bilirubin (tbl) is ≤1.5 x uln at screening and prior to initiating roxadustat treatment. * body weight between 45.0 to 160.0 kg key exclusion criteria: * red blood cell (rbc) transfusion within 4 weeks prior to enrollment * known history of myelodysplastic syndrome or multiple myeloma * known hereditary hematologic disease or other known causes for anemia other than chronic kidney disease (ckd) * known chronic inflammatory disease that is determined by the investigator to be the primary cause of anemia * active or chronic gastrointestinal bleeding * treated with iron-chelating agents within 4 weeks prior to enrollment * history of new york heart association (nyha) class iii or iv congestive heart failure * history of myocardial infarction (mi), acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (excluding vascular dialysis access stenosis/thrombosis) within 12 weeks prior to enrollment * uncontrolled hypertension, in the opinion of the investigator * diagnosis or suspicion of renal cell carcinoma as shown on renal imaging performed within 24 weeks prior to enrollment * history of malignancy, except for cancers determined to be cured or in remission for ≥2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
remission evaluation before intensified treatment in lymphoma: impact of positron emission tomography (pet) using fluorine-18-floro-deoxyglucose (fdg) in the therapeutic prescription. medico-economic randomised study

Conditions: Lymphoma

Summary: this randomised study aimed at evaluating the medical and economical impact of positron emission tomography (pet) using fluorine-18-fluoro-deoxyglucose (fdg) in the therapeutic prescription in patients with hodgkin's lymphoma or with large b and p cell non-hodgkin's lymphoma. the median progression free survival, the costs and the quality of life are compared between two groups : group 1: the results of conventional staging and of the pet are known before stem cell transplantation. group 2: only the results of conventional staging before stem cell transplantation are known before stem cell transplantation.


Eligibility criteria:
inclusion criteria: age over 18, with hodgkin's lymphoma or with large b and p cell non-hodgkin's lymphoma, or after a first-line chemotherapy with at least a residual mass or after induction chemotherapy or at progression. stem cell transplantation would be programmed. patients were required to give their written informed consent. exclusion criteria: progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and basocell skin carcinoma, kidney insufficiency or diabetes. patients would not be pregnant or lactating

Keywords: lymphoma positron emission tomography stem cell transplantation therapeutic impact
long-term venous catheterization in pediatric anesthesia: prevalence and risk factors of dysfunction

Conditions: Catheter Dysfunction

Summary: to evaluate the prevalence of long-life catheters dysfunction and identify the risk factors associated to premature withdrawal in pediatric population. for that: retrospective study, during 3 years, in chu nancy. data collection by informatics file after patient agreement. primary objective: mesure prevalence of long-life catheter dysfunction secondary objectives: * identify risk factors associated to premature withdrawals by thrombotic, infectious, accidental, mechanical complications. * mesure de time spent by anethesist to put long-life catheters in emergency. benefit of creating à vascular access unit.


Eligibility criteria:
inclusion criteria: * long-life catheter (midline, piccline, central venous catheter) * placed in operating room * by anesthesist * in pédiatric population: 0 to 18 years exclusion criteria: * more than 18 years * peripheral venous access * not placed by anesthesist * placed outside operating room

Keywords: pediatric thrombotic catheter infection mechanical complication of catheter
correlation of preoperative indices (serum vit d, calcium, phosphorus, far, plr, sii) on intraoperative bleeding in crs

Conditions: Chronic Rhinosinusitis (CRS) with and Without Nasal Polyps

Summary: the purpose of this observational study was to examine whether preoperative indicators correlate with intraoperative bleeding to facilitate control of intraoperative bleeding.

in this study, we analysed the effect of preoperative inflammation on intraoperative haemorrhage at the subjective and objective levels by measuring a number of indicators (including vit d, ca, p, and some ratios) in the blood specimens and by three scales.blood test indicators can be obtained from routine tests.three scales were obtained by the researcher after interviewing the patients, symptom score (0-15), where higher scores indicate more severe symptoms, lund-kennedy score (0-6), where higher scores indicate higher levels of localised inflammation, lund-mackay score (0-12 unilaterally and 24 bilaterally), where higher scores indicate higher levels of inflammation, and lund-mackay score (0-12 unilaterally and 24 bilaterally), where higher scores indicate higher levels of inflammation.lund-mackay score (0-12 unilaterally, 24 bilaterally), where higher scores represent higher levels of inflammation.final correlation of blood test indices and three scale scores with intraoperative.

Eligibility criteria:
inclusion criteria: clinical diagnosis of chronic rhinosinusitis exclusion criteria: sinus cyst upper respiratory tract infection in the last 1 week use of antiepileptic drugs use of aspirin use of anticoagulant or antiplatelet drugs

Keywords: chronic rhinosinusitis intraoperative haemorrhage
vascular dysfunction during physical inactivity

Conditions: Aging; Vascular Endothelium; Skeletal Muscle

Summary: prolonged periods of reduced activity are associated with decreased vascular function and muscle atrophy. physical inactivity due to a sedentary lifestyle or acute hospitalization is also associated with impaired recovery, hospital readmission, and increased mortality. older adults are a particularly vulnerable population as functional (vascular and skeletal muscle mitochondrial dysfunction) and structural deficits (loss in muscle mass leading to a reduction in strength) are a consequence of the aging process. the combination of inactivity and aging poses an added health threat to these individuals by accelerating the negative impact on vascular and skeletal muscle function and dysfunction. the underlying factors leading to vascular and skeletal muscle dysfunction are unknown, but have been linked to increases in oxidative stress. additionally, there is a lack of understanding of how vascular function is impacted by inactivity in humans and how these changes are related to skeletal muscle function. it is the goal of this study to investigate the mechanisms that contribute to disuse muscle atrophy and vascular dysfunction in order to diminish their negative impact, and preserve vascular and skeletal muscle function.


Eligibility criteria:
inclusion criteria: * individuals who have recently undergone surgery or injury requiring inactivity exclusion criteria: * cardiac abnormalities considered exclusionary by the study physician (congestive heart failure, coronary artery disease, right-to-left shunt) * uncontrolled endocrine or metabolic disease * glomerular filtration rate \< 45 ml/min/1.73 m\^2 or evidence of kidney disease or failure * vascular disease or risk factors of peripheral atherosclerosis * risk of deep vein thrombosis including family history of thrombophilia, pulmonary emboli, deep vein thrombosis * use of anticoagulant therapy * elevated systolic pressure \> 180 or a diastolic blood pressure \> 110 * implanted electronic devices such as pacemakers, infusion pumps, stimulators * cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * currently on a weight-loss diet or body mass index \> 35 kg/m\^2 * inability to abstain from smoking for duration of study * history of \> 20 pack per year smoking * positive for human immunodeficiency virus, hepatitis b or hepatitis c * recent anabolic or corticosteroids use (within 3 months) * subjects with hemoglobin or hematocrit lower than accepted lab values * agitation/aggression disorder * history of stroke with motor disability * recent history (\< 12 months) of gastrointestinal bleed * depression diagnosis * alcohol or drug abuse * liver disease (ast/alt 2 times above the normal limit, hyperbilirubinemia) * respiratory disease (acute upper respiratory infection, history of chronic lung disease with resting oxygen saturation \< 97% on room air) * pregnancy

Keywords: reduced activity muscular atrophy vascular dysfunction
comparison of an exoskeleten with an end-effector for assisted gait training in spinal cord injury

Conditions: Spinal Cord Injuries

Summary: aim is to compare exoskeleton assisted gait training with end-effector assisted gait training in spinal cord rehabilitation

it was planned to evaluate patients aged between 18 and 80 years who will admit to the robotic rehabilitation program due to spinal cord injury. patients will divide into three groups as exoskeleton, end-effector and conventional therapy. exoskeleton and end-effector group will receive robotic therapy 4 days a week besides conventional treatment for 6 weeks. all groups will be evaluated at the start and end of the treatment.

Eligibility criteria:
inclusion criteria: clinical diagnosis of spinal cord injury applying to the hospital for a rehabilitation program exclusion criteria: inadequate body weight (obesity) severe contractures bone instability ( nonstable spinal cord fracture, and severe osteoporosis) circulation problems cardiac nonconformity open wounds on the lower extremities or in the body where they will come into contact with the orthosis uncoordinated, psychotic or aggressive patients serious cognitive disorders long-term infusion therapy hip, knee, ankle arthrodesis epilepsy disproportionate limb or vertebrae, such as bone cartilage dysplasia
compassionate use of evinacumab

Conditions: Pediatric Homozygous Familial Hypercholesterolemia (HoFH); Severe Hypertriglyceridemia (HTG); Dysbetalipoproteinemia (DBL)

Summary: provide compassionate use of evinacumab

compassionate use requests are only being considered in response to individual patient investigational new drug (ind) applications. availability will depend on location.

Eligibility criteria:
buccal film versus iv injection palonosetron for moderately emetogenic chemotherapy induced nausea and vomiting

Conditions: Nausea With Vomiting Chemotherapy-Induced

Summary: phase 2 study to compare efficacy, safety and pk of palonosetron, a long acting 5-ht3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (cinv). subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

this is a phase 2 study to compare efficacy, safety and pk of palonosetron, a long acting 5-ht3 receptor antagonist, by buccal film compared to iv injection for moderately emetogenic chemotherapy-induced nausea or vomiting (cinv) in cancer patients. subjects are randomized into three treatment groups, two with the experimental study drug palonosetron in buccal film at one of two different doses or the control treatment using palonosetron hydrochloride iv injection. palonosetron pk will be assessed in a subgroup of each treatment group.

Eligibility criteria:
inclusion criteria: * with histologically or cytologically confirmed malignant disease; -. be scheduled to receive the first course of mec to be administered on day 1 * using reliable contraceptive measures; * negative serum pregnancy test (if potentially child bearing) exclusion criteria: * received investigational drugs within 30 days before the start of study treatment or scheduled to receive a highly or moderately emetogenic chemotherapeutic agent; * have a clinically unstable seizure disorder with seizure activity requiring anticonvulsant medication; * have severe renal or hepatic impairment; * have positive serology test results; * have a known contraindication to 5-ht3 receptor antagonists; * treated with commercially available or investigative palonosetron formulation within 2 weeks prior to start of study treatment; * allergic to palonosetron or any other 5-ht3 antagonist; * currently a user of any recreational or illicit drugs (including marijuana) or has current evidence of drug or alcohol abuse or dependence as determined by the investigator; * will be receiving stem cell rescue therapy in conjunction with study related course of emetogenic chemotherapy; * received or will receive total body irradiation or radiation therapy to the abdomen or pelvis in the week prior to treatment day 1 and/or during the diary reporting period.
upright open mri for brain imaging in children - a pilot study

Conditions: Brain Tumor

Summary: primary objective to establish feasibility and acceptability of diagnostic brain mri in young children for specified indications using an upright mri system without sedation or anaesthesia. secondary objectives to establish how young children who undergo brain mri using upright mri view the experience to establish how parents / carers of young children who undergo brain mri using the upright mri view the experience for their child and for themselves. to establish how image quality compares between brain mri using the upright mri scanner and the standard mri scanner used in clinical practice.

study design feasibility study collecting data on image quality and experience of upright open mri scanning (performed in addition to standard clinical mri scan), and comparing outcome measures to standard supine mri scans, in children referred for clinical mri scanning for (i) symptoms or signs suggestive of brain tumour and (ii) symptoms or signs suggestive of shunt blockage in children with a ventriculoperitoneal (vp) shunt study participants participants that have been referred for brain mri for symptoms and signs suggestive of brain tumour or who have known vp shunts with a clinical suspicion of shunt dysfunction. 20 participants in total, aiming for an even split between these two groups but will be flexible based on the local clinical case load. planned size of sample (if applicable) 20 young school-aged children (5 to 10 years) referred for brain mri at nuh. the child participant's parents will be simultaneously recruited

Eligibility criteria:
inclusion criteria: * referred for clinical brain mri scan for either: symptoms and signs suggestive of brain tumour, or known vp shunts with a clinical suspicion of shunt dysfunction parental consent and child's agreement to participate inclusion criteria for the adult participants: parent / carer of a child participant exclusion criteria: * contra-indication to mri scans programmable vp shunt requiring re-programming after the research mri unable to sit upright unsupported focal intracranial signs such that a targeted mri protocol would be required (e.g. focal seizures, focal neurology, visual impairment, pituitary dysfunction). exclusion criteria for the adult participants: contra-indication to being in the scan room

Keywords: upright open scanner mri magnetic resonance imaging